Erratum: Disease Activity Free Status: A New End Point for a New Era in Multiple Sclerosis Clinical Research?(JAMA Neurology (2014) 71:3 (269-270) DOI:10.1001/jamaneurol.2013.5486);Disease activity free status: A new end point for a new era in multiple sclerosis clinical research?

JAMA Neurology

Volumn 71, Issue 3, 2014, Pages 269-270

  Bevan, Carolyn J ^a   Cree, Bruce A C ^a  

^a UCSF Multiple Sclerosis Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; CLADRIBINE; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GADOLINIUM PENTETATE; GLATIRAMER; INTERFERON BETA SERINE; NATALIZUMAB; PLACEBO;

CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DISABILITY; DISEASE ACTIVITY; DISEASE ACTIVITY FREE STATUS; DISEASE COURSE; EXPANDED DISABILITY STATUS SCALE; HUMAN; MULTIPLE SCLEROSIS; NEURORADIOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RELAPSE; REMISSION; SHORT SURVEY; TREATMENT OUTCOME;

BIOMEDICAL RESEARCH; HUMANS; MULTIPLE SCLEROSIS; REMISSION INDUCTION;

EID: 84896781696     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2014.1559     Document Type: Erratum

References (7)

1. Anderson JK, Zimmerman L, Caplan L, Michaud K. Measures of rheumatoid arthritis disease activity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score with 28-Joint Counts (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Activity Score (PAS) and Patient Activity Score-II (PASII), Routine Assessment of Patient Index Data (RAPID), Rheumatoid Arthritis Disease Activity Index (RADAI) and Rheumatoid Arthritis Disease Activity Index-5 (RADAI-5), Chronic Arthritis Systemic Index (CASI), Patient-Based Disease Activity Score With ESR (PDAS1) and Patient-Based Disease Activity Score without ESR (PDAS2), and Mean Overall Index for Rheumatoid Arthritis (MOI-RA). Arthritis Care Res (Hoboken). 2011; 63(suppl 11): S14-S36.
2. Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009; 8(3): 254-260.
3. Giovannoni G, Cook S, Rammohan K, et al; CLARITY study group. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurol. 2011; 10(4): 329-337.
4. Kappos LRE-W, O'Connor P, Amato M, Zhang-Auberson L, Tang D, Francis G; on behalf of the FREEDOMS (FTY720 Research Evaluating Effects of Daily Oral therapy in Multiple Sclerosis) Study Group. Fingolimod treatment increases the proportion of patients who are free from disease activity in multiple sclerosis; results from a phase 3, placebo-controlled study (FREEDOMS). Paper presented at: the 63rd Annual Meeting of the American Academy of Neurology. Honolulu, HI; April 9, 2011.
5. Radue EW, O'Connor P, Polman CH, et al; FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) Study Group. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Arch Neurol. 2012; 69(10): 1259-1269.
6. Giovannoni G, Gold R, Kappos L, et al. Analysis of clinical and radiological disease activity-free status in patients with relapsing-remitting multiple sclerosis treated with BG-12: findings from the DEFINE study. J Neurol. 2012; 259: S106-S106.
7. Lublin FD, Cofield SS, Cutter GR, et al; CombiRx Investigators. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol. 2013; 73(3): 327-340.